Chemotherapy & Immunotherapy Options for Genitourinary Malignancies: A Primer for the Advanced Practice Provider Webcast 005IC (2018)
Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, and prostate cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a panel discussion with an interactive component. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included. Session objectives will include familiarity with systemic therapy regimens for these malignancies as well as their specific expected outcomes and side effects.
- Advanced Practice Provider (Nurse Practitioners & Physician Assistants)
After completing this activity, participants will be able to:
- Describe the standard of care chemotherapy regimens for genitourinary malignancies
- Recognize newer immunotherapy options in the treatment of genitourinary malignancies
- Identify and manage the toxicities with relation to these agents
- Identify the survivorship issues surrounding patients on systemic treatments for genitourinary malignancies
Costas Lallas, MD: Nothing to Disclose
Anne Calvaresi, MSN, CRNP: Nothing to Disclose
Edouard Trabulsi, MD, FACS: GenomeDx: Consultant or Advisor; Janssen: Consultant or Advisor, Meeting Participant or Lecturer; Pfizer: Consultant or Advisor, Meeting Participant or Lecturer; Merck: Meeting Participant or Lecturer
Method of Participation
To claim CME credit/hours of participation, the learner must view the webcast, complete the post-test passing with 80% accuracy and submit the activity evaluation.
Estimated time to complete this activity: 2.00 hour
Release Date: June, 2018
Expiration Date: June, 2019
Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation: The American Urological Association designates this enduring material for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1.00 Credit™.
Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
Resolution of Identified Conflict of Interest: All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
Disclaimer: The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.
Acknowledgements: Support provided by an independent education grant from AbbVie, Astellas, Genomic Health, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Medivation, Inc. a Pfizer company, Sanofi Genzyme, AstraZeneca, Genentech and Merck & Co., Inc.
Reproduction Permission: Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Non-Physician Participation